PDF
Stabilization of EREG via STT3B-mediated N-glycosylation is critical for PDL1 upregulation and immune evasion in head and neck squamous cell carcinoma
- Shengming Xu1,2,3,4, Haifeng Wang5, Yu Zhu2,3,4,6, Yong Han1,2,4, Liu Liu1,2,4, Xiangkai Zhang1,2,4, Jingzhou Hu1,2,3,4, Wuchang Zhang2,3, Shengzhong Duan2,3, Jiong Deng7, Zhiyuan Zhang1,2,3,4, Shuli Liu1,2,3,4
Author information
+
1. Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;
2. National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China;
3. Laboratory of Oral Microbiota and Systemic Diseases, College of Stomatology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;
4. Research Unit of Oral and Maxillofacial Regenerative Medicine, Chinese Academy of Medical Sciences, Shanghai, China;
5. Department of Stomatology, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji, China;
6. Department of Implant Dentistry, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;
7. Medical Research Center, Binzhou Medical University Hospital, Binzhou, China
Show less
History
+
Received |
Revised |
Published |
26 Nov 2023 |
16 Mar 2024 |
01 Jan 2024 |
Issue Date |
|
10 Jul 2024 |
|
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
This is a preview of subscription content, contact
us for subscripton.
References
1. Mody M. D., Rocco J. W., Yom S. S., Haddad R. I.& Saba, N. F. Head and neck cancer.Lancet 398, 2289-2299 (2021).
2. Leemans, C. R., Snijders, P. J.F. & Brakenhoff, R. H. The molecular landscape of head and neck cancer.Nat. Rev. Cancer 18, 269-282 (2018).
3. Cavalieri, S.et al.Immuno-oncology in head and neck squamous cell cancers: news from clinical trials, emerging predictive factors and unmet needs.Cancer Treat. Rev. 65, 78-86 (2018).
4. Ferris, R. L.et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck.N. Engl. J. Med. 375, 1856-1867 (2016).
5. Concha-Benavente, F. et al. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer.Cancer Res. 76, 1031-1043 (2016).
6. Du, L.et al.beta-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J. Exp. Med. 217, https://doi.org/10.1084/jem.20191115(2020).
7. Azuma, K.et al.Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.Ann. Oncol. 25, 1935-1940 (2014).
8. Akbay, E. A.et al.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.Cancer Discov. 3, 1355-1363 (2013).
9. Huang, C.et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell 39, 361-379.e316 (2021).
10. Toyoda, H.et al.Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes.J. Biol. Chem. 270, 7495-7500 (1995).
11. Liu, S.et al.Autocrine epiregulin activates EGFR pathway for lung metastasis via EMT in salivary adenoid cystic carcinoma.Oncotarget 7, 25251-25263 (2016).
12. Liu, S.et al.EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.Theranostics 10, 10589-10605 (2020).
13. Yang, J.et al.A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.Nature 586, 572-577 (2020).
14. Song M. J., Lee S. H., Kim E. Y.& Chang, Y. S. Increased number of subclones in lung squamous cell carcinoma elicits overexpression of immune related genes.Transl. Lung Cancer Res. 9, 659-669 (2020).
15. Tang L.Detecting protein glycosylation.Nat. Methods 16, 26(2019).
16. Aebi M.N-linked protein glycosylation in the ER.Biochim. Biophys. Acta 1833, 2430-2437 (2013).
17. Mulagapati, S., Koppolu, V.& Raju, T. S. Decoding of O-linked glycosylation by mass spectrometry.Biochemistry 56, 1218-1226 (2017).
18. Arigoni-Affolter, I. et al. Mechanistic reconstruction of glycoprotein secretion through monitoring of intracellular N-glycan processing.Sci. Adv. 5, eaax8930 (2019).
19. Asano N.Glycosidase inhibitors: update and perspectives on practical use.Glycobiology 13, 93R-104R (2003).
20. Schwarz F.& Aebi, M. Mechanisms and principles of N-linked protein glycosylation.Curr. Opin. Struct. Biol. 21, 576-582 (2011).
21. Breitling J.& Aebi, M. N-linked protein glycosylation in the endoplasmic reticulum.Cold Spring Harb. Perspect. Biol. 5, a013359(2013).
22. Ruiz-Canada, C., Kelleher, D. J. & Gilmore, R. Cotranslational and posttranslational N-glycosylation of polypeptides by distinct mammalian OST isoforms.Cell 136, 272-283 (2009).
23. Hsu, J. M.et al.STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.Nat. Commun. 9, 1908(2018).
24. Casey, S. C.et al.MYC regulates the antitumor immune response through CD47 and PD-L1.Science 352, 227-231 (2016).
25. Delmore, J. E.et al.BET bromodomain inhibition as a therapeutic strategy to target c-Myc.Cell 146, 904-917 (2011).
26. Lopez-Sambrooks, C. et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells.Nat. Chem. Biol. 12, 1023-1030 (2016).
27. Baro M.,Lopez Sambrooks, C., Quijano, A., Saltzman, W. M. & Contessa, J. Oligosaccharyltransferase inhibition reduces receptor tyrosine kinase activation and enhances glioma radiosensitivity.Clin. Cancer Res. 25, 784-795 (2019).
28. Song, X.et al.Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers.Cancer Discov. 10, 1872-1893 (2020).
29. Wang Y. N., Lee H. H., Hsu J. L., Yu D.& Hung, M. C. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.J. Biomed. Sci. 27, 77(2020).
30. Li, C. W.et al.Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.Nat. Commun. 7, 12632(2016).
31. Li, C. W.et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell 33, 187-201.e110 (2018).
32. Sun, C., Mezzadra, R.& Schumacher, T. N. Regulation and function of the PD-L1 checkpoint.Immunity 48, 434-452 (2018).
33. Iwai, Y.et al.Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002).
34. Herbst, R. S.et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature 515, 563-567 (2014).
35. Yang, Y.et al.Palmitoylation stabilizes PD-L1 to promote breast tumor growth.Cell Res. 29, 83-86 (2019).
36. Hsu J. M., Li C. W., Lai Y. J.& Hung, M. C. Posttranslational modifications of PD-L1 and their applications in cancer therapy.Cancer Res. 78, 6349-6353 (2018).
37. Cha, J. H.et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol. Cell 71, 606-620.e607 (2018).
38. Freed, D. M.et al. EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics. Cell 171, 683-695.e618 (2017).
39. Zheng, H.et al.HDAC inhibitors enhance t-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma.Clin. Cancer Res. 22, 4119-4132 (2016).
40. Han, Y.et al.Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade.Cell Death Dis. 12, 993(2021).